Retatrutide Dosage: Reported Research Ranges
Reported in research: 0.5–12 mg once weekly (subcutaneous) in published human trials; practitioner protocols report 1–12 mg per week. Sources vary.
Dosing Protocols Research · Peptide dosage chart · What is Retatrutide? · Research library
Reported ranges by source
| Reported range | Source type | Evidence strength |
|---|---|---|
| 0.5–12 mg once weekly, subcutaneous (arms of 0.5, 1, 4, 8, 9 and 12 mg; some arms started at 2 mg and stepped up) | Human trial (published study) | Human: randomized controlled trials (phase 2 and 3) |
| 1–12 mg per week; the same source also lists 2–4 mg (frequency not stated) | Practitioner protocols | Practitioner protocol (not a clinical trial) |
| 0.1–0.5 mg per week mentioned in transcribed videos | Dr. Trevor reports | Practitioner report (not a clinical trial) |
Amounts are shown as each source reports them. Where sources disagree, the table lists each one; there is no single agreed amount.
Published human trials in our library
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial · PubMed 42810372
- Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes · PubMed 42608321
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial · PubMed 42250575
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study · PubMed 40916752
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial · PubMed 40609566
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA · PubMed 37385280
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial · PubMed 37366315
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial · PubMed 36354040
- Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease · PubMed 41160422
FAQ
What Retatrutide dosage is reported in research?
Reported in research: 0.5–12 mg once weekly (subcutaneous) in published human trials; practitioner protocols report 1–12 mg per week. Sources vary.
Is there human-trial evidence for Retatrutide dosing?
Yes. Published randomized trials in our study library report the amounts in the table above.
Why do the reported Retatrutide amounts differ?
Each source studied or described a different group, form, goal and time frame, so reported amounts vary between sources. PeptideWhiz lists each one with its source type instead of picking a single amount.
Where can I convert a Retatrutide amount into syringe units?
The PeptideWhiz calculator for Retatrutide converts a vial amount, water volume and target amount into mL and syringe units. It does not suggest an amount.
Last updated: November 2, 2026.
Research information only. This page lists amounts as reported in published studies, practitioner protocols and Dr. Trevor reports. It is not medical advice and not a recommendation for any person. Sources vary, and most of these compounds are not approved for the uses discussed.